Defunct Company
Total Trials
12
As Lead Sponsor
As Collaborator
0
Total Enrollment
1,979
NCT00073554
Alfimeprase for Thrombolysis in Acute Peripheral Arterial Occlusion
Phase: Phase 2
Role: Lead Sponsor
Start: Jun 30, 2003
Completion: Not specified
NCT00115999
Study of Alfimeprase to Rapidly Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery on Leg Arteries
Phase: Phase 3
Start: Apr 30, 2005
Completion: Feb 28, 2007
NCT00116012
Anticoagulation With rNAPc2 to Eliminate MACE/TIMI 32
Start: Jun 30, 2005
NCT00346424
Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Central Catheters
Start: Sep 30, 2005
Completion: Dec 31, 2006
NCT00322270
Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Catheters
Start: Jan 31, 2006
NCT00338585
Study of Alfimeprase's Ability to Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery
Start: Apr 30, 2006
Completion: Mar 31, 2007
NCT00443573
Safety Study of Recombinant NAPc2 to Prevent Tumor Progression and Metastases in Metastatic Colon Cancer
Phase: Phase 1/2
Start: Dec 31, 2006
NCT00499902
Phase 2 Proof-of-Concept Study of the Safety and Efficacy of Alfimeprase to Rapidly Open Arteries and Restore Brain Function Following a Stroke
Start: Jun 30, 2007
Completion: May 31, 2008
NCT00808964
Study of NU172 as Anticoagulation in Patients Undergoing Off-pump CABG Surgery
Start: Jan 31, 2013
Completion: Sep 30, 2013
NCT01970501
Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure
Start: Apr 30, 2014
Completion: Dec 28, 2017
NCT04655586
Assessing Safety, Hospitalization and Efficacy of rNAPc2 in COVID-19
Phase: Phase 2/3
Start: Dec 10, 2020
Completion: Mar 7, 2022